Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...
On September 17, 2026, NeurologyLive convened a clinical forum in Philadelphia titled "Recognizing and Treating Plexiform ...
Unlike the antiseizure medications used to manage Dravet syndrome, which act on downstream targets to modulate seizure ...
Lundbeck recently announced that its Lu AF28996, an investigational oral prodrug of a D1-like/D2-like dopamine receptor agonist, was associated with increases in good ON-time and ...
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of ...
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson ...
Investigational oral dopamine agonist prodrug boosts good ON-time, cuts OFF-time and dyskinesia, and reduces levodopa in advanced Parkinson disease, as phase 2 begins. The associate vice president of ...
Extracellular vesicle scores largely remained stable on placebo, whereas KP405 was associated with statistically significant but variable within-subject shifts in insulin signaling, neuroprotection, ...
Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results